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Volume 43, Number 4 Conte et al 751But I think it would have been quite valuable to have a measure of
total graft wall thickening. Unfortunately, we don’t have that type of
data in this study. In regard to the cardiac trial results, all I can say
about that iswhat’s been said publicly in the press release,which is that
PREVENT IV was also negative in terms of the primary study end
points. They are also doing many other analyses in their database and
will be presenting their data very shortly.
Dr Thomas Lindsay (Toronto, Ontario, Canada). I wanted to
ask, as an investigator, how dowe know that we actually delivered the
drug to the vein grafts equally across so many investigational sites? As
you know, pressurizing the device was subject to a little bit of error, I
would imagine, despite the fact that we’d all been trained. So how do
we know that we actually delivered the drug appropriately?
graft implantation.2 EDF-treatment of coronary bypass grafts alsoDr Conte. It’s a terrific question and one that we continue to
wonder about. And I can only give you a partial answer. What was
recorded by studymonitorswere gross problemswith drug delivery in
the operating room if, for example, the device didn’t function or there
was someothermishap indrughandling.That turnedout tobe a very,
very small number of cases. So, of course, we’re left with several
possibilities, including the possibility that the molecular target was
wrong or the possibility that that target is right but was inadequately
treated by the drug either because of the variability in delivery or
perhaps the mode of a single delivery. We just don’t know how to
discriminate those at the present time.Having said that, all the centers
had training with the device, as you know, including either on-site
training or a video, and it’s a fairly simple device to use.INVITED COMMENTARYJoseph L. Mills, MD, Tucson, Ariz
The present report by Conte et al of PREVENT III, a prospec-
tive, randomized trial of molecular therapy for the prevention of vein
graft stenosis, is a landmark study in many important respects. Autol-
ogous vein grafts, in fact nearly all forms of open or endoluminal
intervention for atherosclerosis, are plaguedby restenosis, a significant
clinical problem that develops in at least one third of patients.
Current paradigms attribute early or intermediate restenosis
to smooth muscle cell (SMC) proliferation and resultant myointi-
mal hyperplasia. Transcription factor E2F is thought to play a
critical role in coordinating the expression of genes important in
the regulation of cellular proliferation. This human study involved
the incubation of vein grafts with placebo or edifoligide (EDF), an
E2F decoy. The decoy consists of short, double-stranded oligode-
oxynucleotides (ODN) bearing a consensus-binding site for a
specific transcription factor. Once delivered, the ODN competi-
tively inhibit the targeted transcription factor. The decoy used in
this study targeted E2F and had been demonstrated in a rabbit
model of intimal hyperplasia to reduce target gene (eg, PCNA)
expression and SMC proliferation. Two phase 1-2 studies in hu-
mans demonstrated that this approach was safe and feasible and
confirmed target gene inhibition in the graft wall.
In this phase 3 trial, 1404 patients undergoing infrainguinal
vein bypass for critical limb ischemia were randomized at 83 study
sites; 1138 patients (563 EDF, 575 placebo) completed a 1-year
clinical and duplex follow-up. In these high-risk patients, 75% of
whom presented with tissue loss, perioperative mortality was 2.7%,
and the incidence of early-graft occlusion was only 5.2%. A total of
81% of enrolled patients completed the 1-year follow-up, and only
3.2% were lost to follow-up or withdrawn. Compliance with the
surveillance protocol was excellent, a difficult proposition in such
patients enrolled at so many sites.
Now for the bad news: despite a thoughtful, well-conceived trial
design and an impeccably executed study, with high-quality surgical
results at multiple centers, the proposedmolecular therapy was found
to result in no significant improvement in any of the trial design
primary end points of nontechnical graft reintervention or major
amputation due to index graft failure, or secondary end points of
all-cause graft failure,70% restenosis, survival free of amputation or
reintervention, and nontechnical primary graft patency.
The only positive spin was the detection of a small, but
significantly improved, secondary patency rate in EDF-treated vein
grafts, an end point that has never been considered important for
vein grafts and that likely occurred by chance alone due to exuber-
ant statistical analysis of a large number of patients.
In 2006, just as in 1973, approximately 33% of infrainguinal
grafts develop restenosis or fail. These data confirm Szilagyi’s1
landmark observations and the long succession of duplex surveil-
lance studies on the incidence of stenosis after lower-extremity veinwas recently reported to confer no benefit in a randomized, pro-
spective trial of 3000 patients (PREVENT IV Trial).3
Level I evidence for much of what we do in vascular surgery is
sadly lacking. This study is exceedingly important for several reasons.
It demonstrates that large, prospective,multicenter trials of important
problems in peripheral vascular disease are possible. The trial design
and study execution were nearly flawless (except for the somewhat
unconventional primary study end point!). A high-tech, novel molec-
ular therapy was designed that was easy and safe to administer. The
low mortality, respectable assisted-graft patency, and high limb-sal-
vage rates in a large group of patients with critical limb ischemia were
excellent, attesting to the ability of vascular surgeons from a variety of
academic andprivate settings to provide superb surgical care andgood
clinical outcomes. Publication of the study, despite its negative result,
is also of importance in an age in which negative results are often
withheld by companies, sponsors, or investigators with a personal or
financial interest in the success of the study product or device.
Themost important issue, then, iswhydid edifoligide (EDF) fail?
A rabbit, even onewith awatch in his waistcoat-pocket, is not human.
I fear vascular biologists, like Alice, have gone “down the rabbit-
hole”, “never once consideringhow in theworld . . .to get out again.”
Animal studies of intimal hyperplasia, predominantly rabbit carotid
artery balloon injury or carotid-jugular interposition graft models,
have failed miserably to predict what happens in people. I think it is
time for our basic scientists to crawl out of the rabbit hole, readjust to
the light, and look at the issue with fresh eyes. More effort should be
directed toward the roles of a variety of other cells and biologic
processes rather than the persistent myopic focus on smooth muscle
cell proliferation.4 The role of inflammatory cells and matrix deposi-
tion are worthy contenders. The restenosis process is likely more
complex than we have been willing to acknowledge. It may require a
drug cocktail to induce it into a state of suitable slumber.
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